Claudine Zachara Net Worth

The estimated Net Worth of Claudine Zachara is at least $26.4 Thousand dollars as of 29 February 2012. Claudine Zachara owns over 200 units of Heska stock worth over $26,398 and over the last 13 years Claudine sold HSKA stock worth over $0.

Claudine Zachara HSKA stock SEC Form 4 insiders trading

Claudine has made over 1 trades of the Heska stock since 2012, according to the Form 4 filled with the SEC. Most recently Claudine bought 200 units of HSKA stock worth $1,950 on 29 February 2012.

The largest trade Claudine's ever made was buying 200 units of Heska stock on 29 February 2012 worth over $1,950. On average, Claudine trades about 67 units every 0 days since 2011. As of 29 February 2012 Claudine still owns at least 220 units of Heska stock.

You can see the complete history of Claudine Zachara stock trades at the bottom of the page.

What's Claudine Zachara's mailing address?

Claudine's mailing address filed with the SEC is Heska, 3760, Rocky Mountain Avenue, Loveland, Larimer County, Colorado, 80538, United States.

Insiders trading at Heska

Over the last 21 years, insiders at Heska have traded over $40,831,198 worth of Heska stock and bought 747,946 units worth $2,470,701 . The most active insiders traders include Jason A Napolitano, Robert B Grieve, and Robert L Antin. On average, Heska executives and independent directors trade stock every 20 days with the average trade being worth of $1,041,873. The most recent stock trade was executed by Kevin S. Wilson on 6 January 2023, trading 11,018 units of HSKA stock currently worth $645,875.

What does Heska do?

heska corporation (nasdaq: hska) is dedicated to perfecting and supporting the core technology and services that truly impact the quality of pet care and help to ensure positive outcomes for veterinarians and their patients. heska was created by veterinary professionals for veterinary professionals. our pledge to customers is to stand behind sound science, following best medical practices. heska’s line of diagnostic and imaging advancements include state-of-the-art chemistry, hematology, and blood gas & electrolyte systems, as well as single-step heartworm, early renal healthscreens, allergy testing and allergy treatment. heska also leads the way with the latest hd digital radiography, digital ultrasound, and pacs imaging technologies from cuattro. we help veterinary practices discover the right product solutions for their clients and patients; improving patient care, productivity and profitability. heska’s corporate headquarters are in loveland, colorado. we provide our products a

Complete history of Claudine Zachara stock trades at Heska

Heska executives and stock owners

Heska executives and other stock owners filed with the SEC include:

• Jason Aroesty,
  Executive Vice President - International Diagnostics
• Catherine Grassman,
  Chief Financial Officer, Executive Vice President
• Kevin S. Wilson,
  CEO, Pres & Director
• Kevin Wilson,
  President, Chief Executive Officer, Director
• Catherine I. Grassman CPA,
  Exec. VP & CFO
• Steven M. Eyl,
  Exec. VP, Chief Commercial Officer & Pres of scil animal care company
• Dr. Nancy Wisnewski,
  Exec. VP & COO
• Nancy Wisnewski,
  Chief Operating Officer, Executive Vice President
• Steven Eyl,
  Executive Vice President, Chief Commercial Officer, Heska and President, scil animal care
• Scott Humphrey,
  Independent Chairman of the Board
• Bonnie Trowbridge,
  Independent Director
• Sharon Larson,
  Independent Director
• David Sveen,
  Independent Director
• Mark Furlong,
  Independent Director
• Robert Antin,
  Director
• Jon Aagaard,
  Director, Investor Relations
• Stephen Davis,
  Director
• Christopher Sveen,
  Executive Vice President, Chief Administrative Officer and General Counsel, Heska and President, Diamond Animal Health
• Anthony C. Providenti Jr.,
  Exec. VP of Corp. Devel.
• Laurie E. Peterson,
  VP of Heska Des Moines
• Daniel J. Pollack,
  VP of Imaging Operations, Treasurer & Assistant Sec.
• Eleanor F. Baker,
  Exec. VP, MD & COO of scil animal care company
• Jason D. Aroesty,
  Exec. VP of Global Sales and Marketing
• Steve Asakowicz,
  EVP, Comp. Animal Health Sales
• Carol Wrenn,
  Director
• Rod Lippincott,
  EVP, Comp. Animal Health Sales
• John Mc Mahon,
  VP, Fin. Oper. & Controller
• Michael J Mc Ginley,
  EVP, Global Operations
• G Irwin Gordon,
  Director
• John R Flanders,
  V.P., General Counsel
• Gerald L Snodgrass,
  VP, Sales
• Coast Investors Ltd Pacific,
  10% owner
• Joseph H Ritter,
  VP, Marketing & Int'l Bus.
• Ventures Ii, L.P.Charter Ve...,
  
• A Barr Dolan,
  Director
• Carol Talkington Verser,
  Exec.V.P. Intel Prop & Bus Dev
• Lynnor B Stevenson,
  Director
• Life Sciences I Iv Llc Charter,
  10% owner
• Elisabeth H Demarse,
  Director
• Tina Susan Nova,
  Director
• Ventures Ii, L.P. Charter,
  10% owner
• Lyle A Hohnke,
  Director
• Dan T Stinchcomb,
  Exec. V.P., Research and Dev.
• Albert Jr Honsch,
  Vice President, Sales
• Jason A Napolitano,
  Chief Strategy Officer
• Robert B Grieve,
  Chief Executive Officer
• William A Aylesworth,
  Director
• Joseph Aperfine,
  EVP, Sales and Marketing
• Master Fund, L.P.Cmc Master...,
  
• Michael A Bent,
  V.P.Actg. Officer & Controller
• Claudine Zachara,
  
• Master Fund, L.P.Cmc Master...,
  
• John F Sasen,
  Director
• Peter Eio,
  Director
• Louise L. Mc Cormick,
  Director
• Joachim A. Hasenmaier,
  
• Eleanor F. Baker,
  EVP, Managing Dir. & COO, scil
• Anthony C. Jr. Providenti,
  EVP, Corporate Development
• Sharon J. Maples,